vs

Side-by-side financial comparison of EXTREME NETWORKS INC (EXTR) and Sarepta Therapeutics, Inc. (SRPT). Click either name above to swap in a different company.

Sarepta Therapeutics, Inc. is the larger business by last-quarter revenue ($369.6M vs $316.9M, roughly 1.2× EXTREME NETWORKS INC). EXTREME NETWORKS INC runs the higher net margin — 3.3% vs -111.5%, a 114.9% gap on every dollar of revenue. On growth, EXTREME NETWORKS INC posted the faster year-over-year revenue change (11.4% vs -42.1%). Sarepta Therapeutics, Inc. produced more free cash flow last quarter ($127.6M vs $7.8M). Over the past eight quarters, EXTREME NETWORKS INC's revenue compounded faster (11.1% CAGR vs 1.4%).

Extreme Networks, Inc. is an American networking company based in Morrisville, North Carolina. Extreme Networks designs, develops, and manufactures wired and wireless network infrastructure equipment and develops the software for network management, policy, analytics, security and access controls.

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.

EXTR vs SRPT — Head-to-Head

Bigger by revenue
SRPT
SRPT
1.2× larger
SRPT
$369.6M
$316.9M
EXTR
Growing faster (revenue YoY)
EXTR
EXTR
+53.5% gap
EXTR
11.4%
-42.1%
SRPT
Higher net margin
EXTR
EXTR
114.9% more per $
EXTR
3.3%
-111.5%
SRPT
More free cash flow
SRPT
SRPT
$119.8M more FCF
SRPT
$127.6M
$7.8M
EXTR
Faster 2-yr revenue CAGR
EXTR
EXTR
Annualised
EXTR
11.1%
1.4%
SRPT

Income Statement — Q4 FY2026 vs Q4 FY2025

Metric
EXTR
EXTR
SRPT
SRPT
Revenue
$316.9M
$369.6M
Net Profit
$10.6M
$-412.2M
Gross Margin
61.7%
Operating Margin
5.5%
-111.4%
Net Margin
3.3%
-111.5%
Revenue YoY
11.4%
-42.1%
Net Profit YoY
202.9%
-359.2%
EPS (diluted)
$0.08
$-3.92

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EXTR
EXTR
SRPT
SRPT
Q2 26
$316.9M
Q4 25
$317.9M
$369.6M
Q3 25
$310.2M
$370.0M
Q2 25
$307.0M
$513.1M
Q1 25
$284.5M
$611.5M
Q4 24
$279.4M
$638.2M
Q3 24
$269.2M
$429.8M
Q2 24
$256.7M
$360.5M
Net Profit
EXTR
EXTR
SRPT
SRPT
Q2 26
$10.6M
Q4 25
$7.9M
$-412.2M
Q3 25
$5.6M
$-50.6M
Q2 25
$-7.8M
$196.9M
Q1 25
$3.5M
$-447.5M
Q4 24
$7.4M
$159.0M
Q3 24
$-10.5M
$33.6M
Q2 24
$-54.2M
$6.5M
Gross Margin
EXTR
EXTR
SRPT
SRPT
Q2 26
61.7%
Q4 25
61.4%
Q3 25
60.6%
59.3%
Q2 25
61.6%
70.3%
Q1 25
61.7%
77.5%
Q4 24
62.7%
Q3 24
63.0%
78.7%
Q2 24
44.7%
87.6%
Operating Margin
EXTR
EXTR
SRPT
SRPT
Q2 26
5.5%
Q4 25
4.1%
-111.4%
Q3 25
3.6%
-27.9%
Q2 25
-0.4%
22.5%
Q1 25
3.6%
-49.1%
Q4 24
4.5%
25.3%
Q3 24
-1.8%
5.2%
Q2 24
-19.1%
-0.2%
Net Margin
EXTR
EXTR
SRPT
SRPT
Q2 26
3.3%
Q4 25
2.5%
-111.5%
Q3 25
1.8%
-13.7%
Q2 25
-2.5%
38.4%
Q1 25
1.2%
-73.2%
Q4 24
2.6%
24.9%
Q3 24
-3.9%
7.8%
Q2 24
-21.1%
1.8%
EPS (diluted)
EXTR
EXTR
SRPT
SRPT
Q2 26
$0.08
Q4 25
$0.06
$-3.92
Q3 25
$0.04
$-0.50
Q2 25
$-0.07
$1.89
Q1 25
$0.03
$-4.60
Q4 24
$0.06
$1.56
Q3 24
$-0.08
$0.34
Q2 24
$-0.40
$0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EXTR
EXTR
SRPT
SRPT
Cash + ST InvestmentsLiquidity on hand
$210.1M
$939.6M
Total DebtLower is stronger
$829.0M
Stockholders' EquityBook value
$1.1B
Total Assets
$1.2B
$3.3B
Debt / EquityLower = less leverage
0.73×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EXTR
EXTR
SRPT
SRPT
Q2 26
$210.1M
Q4 25
$219.8M
$939.6M
Q3 25
$209.0M
$851.0M
Q2 25
$231.7M
$800.1M
Q1 25
$185.5M
$522.8M
Q4 24
$170.3M
$1.4B
Q3 24
$159.5M
$1.2B
Q2 24
$156.7M
$1.5B
Total Debt
EXTR
EXTR
SRPT
SRPT
Q2 26
Q4 25
$829.0M
Q3 25
$140.5M
Q2 25
$180.0M
Q1 25
Q4 24
$1.1B
Q3 24
$1.2B
Q2 24
$190.0M
$1.2B
Stockholders' Equity
EXTR
EXTR
SRPT
SRPT
Q2 26
Q4 25
$95.9M
$1.1B
Q3 25
$68.6M
$1.3B
Q2 25
$65.6M
$1.4B
Q1 25
$71.7M
$1.1B
Q4 24
$51.2M
$1.5B
Q3 24
$32.7M
$1.2B
Q2 24
$25.3M
$1.1B
Total Assets
EXTR
EXTR
SRPT
SRPT
Q2 26
$1.2B
Q4 25
$1.2B
$3.3B
Q3 25
$1.2B
$3.5B
Q2 25
$1.2B
$3.7B
Q1 25
$1.1B
$3.5B
Q4 24
$1.1B
$4.0B
Q3 24
$1.1B
$3.6B
Q2 24
$1.0B
$3.4B
Debt / Equity
EXTR
EXTR
SRPT
SRPT
Q2 26
Q4 25
0.73×
Q3 25
0.11×
Q2 25
2.74×
Q1 25
Q4 24
0.74×
Q3 24
1.01×
Q2 24
7.52×
1.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EXTR
EXTR
SRPT
SRPT
Operating Cash FlowLast quarter
$50.3M
$131.2M
Free Cash FlowOCF − Capex
$7.8M
$127.6M
FCF MarginFCF / Revenue
2.5%
34.5%
Capex IntensityCapex / Revenue
1.0%
Cash ConversionOCF / Net Profit
4.75×
TTM Free Cash FlowTrailing 4 quarters
$105.3M
$-307.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EXTR
EXTR
SRPT
SRPT
Q2 26
$50.3M
Q4 25
$50.1M
$131.2M
Q3 25
$-14.0M
$-14.6M
Q2 25
$81.9M
$261.3M
Q1 25
$30.0M
$-583.4M
Q4 24
$21.5M
$92.0M
Q3 24
$18.6M
$-70.7M
Q2 24
$15.5M
$14.9M
Free Cash Flow
EXTR
EXTR
SRPT
SRPT
Q2 26
$7.8M
Q4 25
$43.0M
$127.6M
Q3 25
$-20.9M
$-37.5M
Q2 25
$75.3M
$229.5M
Q1 25
$24.2M
$-627.1M
Q4 24
$16.1M
$54.0M
Q3 24
$11.7M
$-108.0M
Q2 24
$11.0M
$-14.2M
FCF Margin
EXTR
EXTR
SRPT
SRPT
Q2 26
2.5%
Q4 25
13.5%
34.5%
Q3 25
-6.7%
-10.1%
Q2 25
24.5%
44.7%
Q1 25
8.5%
-102.5%
Q4 24
5.8%
8.5%
Q3 24
4.3%
-25.1%
Q2 24
4.3%
-3.9%
Capex Intensity
EXTR
EXTR
SRPT
SRPT
Q2 26
Q4 25
2.2%
1.0%
Q3 25
2.2%
6.2%
Q2 25
2.2%
6.2%
Q1 25
2.0%
7.1%
Q4 24
1.9%
6.0%
Q3 24
2.6%
8.7%
Q2 24
1.7%
8.1%
Cash Conversion
EXTR
EXTR
SRPT
SRPT
Q2 26
4.75×
Q4 25
6.37×
Q3 25
-2.49×
Q2 25
1.33×
Q1 25
8.67×
Q4 24
2.92×
0.58×
Q3 24
-2.10×
Q2 24
2.31×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EXTR
EXTR

Product$199.4M63%
Subscription and support$117.5M37%

SRPT
SRPT

Pmo Products$202.5M55%
Elevidys$110.4M30%
Other$56.7M15%

Related Comparisons